Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 10:11:175-190.
doi: 10.33393/grhta.2024.3062. eCollection 2024 Jan-Dec.

Analisi di impatto sul budget sanitario italiano di roxadustat per il trattamento dell’anemia da malattia renale cronica

[Article in Italian]
Affiliations

Analisi di impatto sul budget sanitario italiano di roxadustat per il trattamento dell’anemia da malattia renale cronica

[Article in Italian]
Chiara Bini et al. Glob Reg Health Technol Assess. .

Abstract

Objective:: The aim of this study was to evaluate the economic consequences of the introduction of roxadustat on the market as treatment for chronic kidney disease (CKD)-related anaemia in Italy.

Method:: A budget impact model was developed to assess the economic impact of the introduction of roxadustat for the management of patient with CKD-related anaemia. The analysis was conducted considering National Health Service (NHS) perspective and three years’ time horizon. Eligible population for the treatment with roxadustat was estimated through published literature and clinicians’ support. Direct healthcare costs included drug acquisition (list prices for base case) and administration costs, monitoring costs, cost per blood transfusion, costs related to the management of adverse events and dialysis costs.

Results:: The model estimated a three years expenditure associated with the management of patients with CKD-related incident anaemia in Italy of about € 260 and € 44.6 million for non-dialysis dependent (NDD) and dialysis-dependent (DD) patients respectively. The introduction of roxadustat on the market could generate a reduction in the expenditure related to the iron supplementation both for NDD and for DD patients (−€ 397,305 and −€ 50,135 over three years of the analysis, respectively) and a reduction in the pharmaceutical expenditure for NDD patients (−€ 2.3 million, −€ 7.5 million and −€ 13 million at first, second and third year of the analysis). Overall, the introduction of roxadustat could generate a saving for NHS approximately equal to € 2.3, € 7.5 and € 13 million at first, second and third year of the analysis.

Conclusion:: The introduction of roxadustat could generate a reduction in the expenditure for the management of patients with CKD anaemia. A scenario analysis which used tender prices for ESAs and hypothesis of confidential discount for roxadustat showed that the saving for NHS will be kept if roxadustat’s discount is greater than 60.3%.

PubMed Disclaimer

Figures

FIGURA 1 -
FIGURA 1 -
Struttura del modello di impatto sul budget in forma grafica.
FIGURA 2 -
FIGURA 2 -
Stima della popolazione eleggibile al trattamento con roxadustat.
FIGURA 3 -
FIGURA 3 -
Spesa totale per anno e scenario di analisi e impatto sul budget: popolazione NDD (3A), popolazione DD (3B).
FIGURA 4 -
FIGURA 4 -
Risultati dell’analisi di sensibilità deterministica: popolazione NDD (4A), popolazione DD (4B).

References

    1. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity Vitamin and Mineral Nutrition Information System. Geneva,: World Health Organization,; 2011. [Accessed March; 2024 ]. Online (WHO/NMH/NHD/MNM/11.1).
    1. Mennini FS. M.A., Viti R, Bini C, Maffei P, Pivonello R. Analisi di impatto di budget di pasireotide in pazienti con acromegalia nella prospettiva del Sistema Sanitario Nazionale. IN PUBBLICATION; 2016
    1. Cases-Amenós A, Martínez-Castelao A, Fort-Ros J . Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study. 2. Vol. 34. Nefrologia.; 2014. Investigadores del Estudio Micenas I. pp. 189–198. - PubMed
    1. De Nicola L, Minutolo R, Chiodini P et al. SIN-TABLE CDK Study Group. Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: a prospective cohort study in outpatient renal clinics. Am J Nephrol. 2010;32(6):533–540. doi: 10.1159/000321468. - DOI - PubMed
    1. Minutolo R, Locatelli F, Gallieni M et al. REport of COmorbidities in non-Dialysis Renal Disease Population in Italy (RECORD-IT) Study Group. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant. 2013;28(12):3035–3045. doi: 10.1093/ndt/gft338. - DOI - PubMed

LinkOut - more resources